These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3174 related articles for article (PubMed ID: 12928754)

  • 1. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
    Kohrt HE; Patel S; Ho M; Owen T; Pollyea DA; Majeti R; Gotlib J; Coutre S; Liedtke M; Berube C; Alizadeh AA; Medeiros BC
    Am J Hematol; 2010 Nov; 85(11):877-81. PubMed ID: 20872554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
    Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
    Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
    Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J
    Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
    Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 159.